On the stock market since 2021, it operates in the world of heavy industry. It has 3,190 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (3% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 10% a year on average.
A loss of $11.6M against $721.9M in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 125 sells against just 38 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, HRT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: HRT has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.